BioAge Labs, Inc. (BIOA)

BioAge Labs, Inc. is a clinical-stage biotechnology company developing therapies for metabolic diseases, including obesity, by targeting the biology of aging. The company draws on a discovery platform built from long-term human aging cohorts with linked biological samples and health records, which it uses to identify molecular pathways associated with healthy aging.

Its pipeline includes small-molecule inhibitors of NLRP3, an inflammation-related protein, including a brain-penetrant candidate being studied for obesity and related metabolic and inflammatory conditions. The company also pursues discovery programs and research collaborations with larger pharmaceutical partners based on targets identified by its platform.

BioAge Labs is headquartered in Richmond, California, and completed its initial public offering on Nasdaq in 2024.